MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Milder presentation in two compound heterozygote cases of spastic paraplegias type 5

    A. Zolin, S. Lakhani, H. Sarva (New York, USA)

    Objective: Describing two mild compound heterozygote SPG5A cases. Background: Hereditary spastic paraplegia type 5 (SPG5A) is an autosomal recessive neurodegenerative disease caused by variants in…
  • 2022 International Congress

    Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study

    E. Peña, C. Borrué, M. Mata, JC. Martínez-Castrillo, A. Alonso-Canovas, JL. Chico, L. López-Manzanares, M. Llanero, J. Herreros-Rodríguez, A. Esquivel, T. Maycas-Cepeda, C. Ruíz-Huete (Madrid, Spain)

    Objective: To assess the role of different factors in the antidepressant effect of safinamide in Parkinson’s disease (PD) Background: SADNESS-PD was a real-life, multicenter, retrospective…
  • 2022 International Congress

    Apathy and Volume of Tissue Activated (VTA) following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Cohort

    T. Stiep, A. Ramirez-Zamora, J. Wong, A. Tröster, R. Jain, L. Chen, M. Malek, M. Okun (Gainesville, USA)

    Objective: To determine frequency and/or predictors of improvement or worsening of apathy, we evaluated this behavior among those who received bilateral subthalamic deep brain stimulation…
  • 2022 International Congress

    Metabolic Biomarkers of Parkinson’s Disease in Peripheral Tissue

    L. Mischley, E. Shankland, S. Liu, S. Bhayana, D. Marcinek (Seattle, USA)

    Objective: The goal of this study was to use magnetic resonance spectroscopy (MRS) to test whether muscles of individuals with Parkinson’s disease (PD) possess a…
  • 2022 International Congress

    Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan

    E. Zhunusova, C. Shambetova, A. Il'Yazova (Bishkek, Kyrgyzstan)

    Objective: The aim of this study was to determine differences between Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in PD patients from Kyrgyzstan.…
  • 2022 International Congress

    Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey

    F. de Renzis, L. Graham, M. Meinders (Orpington, United Kingdom)

    Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…
  • 2022 International Congress

    Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa

    R. Pahwa, M. Soileau, D. Standaert, V. Fung, T. Kimber, I. Malaty, A. Merola, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, N. Fisseha, A. Jeong, M. Facheris, P. Kukreja, J. Zamudio, J. Aldred (Kansas City, USA)

    Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…
  • 2022 International Congress

    Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)

    C. Vermeiren, A. Ates, F. Bouzom, A. Delaunois, M. Gillard, B. Kenda, A. Ousset, L. Provins, D. Skolc, A. Valade, M. Vanmeulder, M. Wood, Y. Lamberty (Braine-l'Alleud, Belgium)

    Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…
  • 2022 International Congress

    Deep Brain Stimulation in Parkinson’s disease: Challenges of a young experience in southern Morocco

    Y. Naji, K. Saghir, M. Chraa, N. Kissani (Marrakech, Morocco)

    Objective: The objective of our research was to describe the epidemiological, therapeutic features and effectiveness of deep brain stimulation in operated patients. To cite the…
  • 2022 International Congress

    CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy

    P. Kanovsky, K. Bucilova, M. Chudackova, D. Konickova, K. Pekarova, K. Sklenarova, M. Kaiserova, S. Kurcova, M. Nevrly, J. Zapletalova, M. Strnad, K. Mensikova (Olomouc, Czech Republic)

    Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley